Clinical trial
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
NCT00407537 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00407537 |
|---|---|
| Title | Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors |
| Official title | A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice |
| Acronym | CRUCIAL |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Amlodipine besylate/atorvastatin calcium single pill combination |
| Enrollment | 1,531 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 5, 2006 |
| Last update posted | Jan 28, 2021 |
| Countries | Costa Rica, Croatia, Czechia, Dominican Republic, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Mexico, Panama, Philippines and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: